TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05523570
Drug: HNC364
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
Study: NCT05073250
Drug: IBI376
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.
Study: NCT05965102
Drug: Tirelizumab；Chemotherapy monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirelizumab combined with chemotherapy in first-line treatment of relapsed/metastatic non-small cell lung cancer with ECOG PS score of 2
Study: NCT06616974
Drug: TX000045- Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
Study: NCT06616974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
Study: NCT05248984
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg
Study: NCT05287503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipients
Study: NCT06287437
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
Study: NCT06287437
Drug: HRS9531 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 placebo low frequency injection for 12 weeks.
Study: NCT04701034
Drug: Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
Study: NCT04701034
Drug: Prednisolone Tablets
Normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg before ET and 10 mg after ET until gestational week 8+0
Study: NCT04701034
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet before ET and 2 tablets after ET until gestational week 8+0
Study: NCT05585931
Drug: TPN171H 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
Study: NCT05585931
Drug: TPN171H Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were given Placebo with 240 mL warm water under fasting condition.
Study: NCT04958382
Drug: medium/long chain fat emulsion injection (C8-24Ve)
Approvals — FDA: no, EMA: no, PMDA: no
Description: at the infusion rate of 25-30 mL/h
Study: NCT06580327
Drug: continuous epidural infusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study: NCT01161394
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06023420
Drug: 4 Herbs Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 herbs formula dose: 5g/day
Study: NCT04819906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five placebo tablets orally once
Study: NCT04880382
Drug: ICI treatment discontinuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
Study: NCT04880382
Drug: ICI treatment continuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
Study: NCT05045313
Drug: DBPR108 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DBPR108, tablet, oral
Study: NCT05365659
Drug: IKS03
Normalized name: Ibuprofen Potassium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Study: NCT06168318
Drug: VH4004280 Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.
Study: NCT06168318
Drug: VH4004280 Formulation D
Normalized name: Rho(D) Unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.
Study: NCT05234320
Drug: CG-SpikeDown, intranasal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
Study: NCT04754802
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Study: NCT03239236
Drug: Anesthetics
Normalized name: ANESTHETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
Study: NCT06290219
Drug: Zinc Gluconate 10 MG Oral Tablet
Normalized name: zinc gluconate 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet three times a day for a period of 12 weeks
Study: NCT05754424
Drug: Humulin R 500 UNT/ML Injectable Solution
Normalized name: Humulin R 500 UNT/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin
Study: NCT06014528
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg QD orally (PO)
Study: NCT06014528
Drug: Placebo of IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg QD orally (PO)
Study: NCT06014528
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
Study: NCT05201638
Drug: Placebo matching IMU-838 tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Study: NCT04845646
Drug: ASC41
Normalized name: Ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg/tablet
Study: NCT04845646
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg/capsule
Study: NCT05032326
Drug: Follow-up study of the treated cohort
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
Study: NCT05022563
Drug: Parenteral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral anticoagulant only
Study: NCT06616922
Drug: RD03/2016 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
Study: NCT05445609
Drug: VLP-encapsulated TLR9 Agonist CMP-001,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC or IT
Study: NCT04647383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study: NCT05540873
Drug: YYB-103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
Study: NCT04858659
Drug: PK101-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet at each time, 2 times a day
Study: NCT04858659
Drug: PK101 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet at each time, 2 times a day
Study: NCT04858659
Drug: PK101-002 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet at each time, 2 times a day
Study: NCT05752916
Drug: Antiplatelet Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single antiplatelet therapy-choice at the discretion of the clinician. Aspirin will be the choice of most physicians, some will choose clopidogrel.
Study: NCT05896969
Drug: SNK-396 - MAD Cohort
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
Study: NCT05327855
Drug: OPL-0301 Dose 1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Study: NCT05327855
Drug: OPL-0301 Dose 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Study: NCT05327855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Study: NCT04689347
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: leucovorin 200 mg/sqm intravenous infusion every 2 weeks
Study: NCT04689347
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
Study: NCT05127473
Drug: Mim8 B, 10 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Study: NCT05127473
Drug: Mim8 B, 100 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Study: NCT05127473
Drug: Mim8 B, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be used to dilute the IMP to different Mim8 concentrations
Study: NCT06160414
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Rosuvastatin orally, after fasting.
Study: NCT06160414
Drug: ALXN2080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ALXN2080 orally, after fasting.
Study: NCT04601233
Drug: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self injection testosterone treatment
Study: NCT05557448
Drug: TYNADOTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Study: NCT05557448
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
Study: NCT05856513
Drug: ZSP1273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive ZSP1273 orally.
Study: NCT06329791
Drug: AZR-MD-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZR-MD-001 sterile ophthalmic ointment 0.5%
Study: NCT05002686
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study: NCT04387734
Drug: Platform
Normalized name: Autolet Platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: The applications of the platform DMTs will follow the FDA-approved regulations.
Study: NCT06655883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06657105
Drug: EE/LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/LNG tablet will be administered orally.
Study: NCT04776499
Drug: Propylthiouracil, Riociguat, Perphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg
Study: NCT04714151
Drug: K-877 ER 0.2 mg/day (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 ER 0.2 mg tablet
Study: NCT04714151
Drug: K-877 ER 0.4 mg/day (once daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 ER 0.4 mg tablet
Study: NCT06289829
Drug: remifentanil of the assigned dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
Study: NCT06446310
Drug: QLG2198
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Study: NCT06446310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
Study: NCT04694612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
Study: NCT05118516
Drug: ASC43F
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
Study: NCT06188507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT06494280
Drug: continuous epidural infusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study: NCT06207123
Drug: LP-118
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.
Study: NCT06504901
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 bid po, d1-d14
Study: NCT06207123
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
Study: NCT05742919
Drug: NNC0194-0499
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
Study: NCT05742919
Drug: NC0194-0499
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
Study: NCT05009368
Drug: Drug: Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTL0902, single dose, daily, repeated oral administration for 7 days
Study: NCT05009368
Drug: Drug: Treatment C
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
Study: NCT00002262
Drug: Tumor Necrosis Factor
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04528199
Drug: [18F]FLOR (FC303) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
Study: NCT04924374
Drug: anti PD1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti PD1 therapy every 2-3 weeks
Study: NCT02707926
Drug: Anti-HIV Agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy to treat HIV infection
Study: NCT06126861
Drug: [14C]LP-168
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
Study: NCT04669288
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging.
Study: NCT04669288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging.
Study: NCT05944458
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluimucil 600 mg iv to be taken twice daily as infusion
Study: NCT04588441
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
Study: NCT06240689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
Study: NCT05016687
Drug: CUR-N399
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CUR-N399 will be administered as oral capsules.
Study: NCT05016687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching CUR-N399 will administered.
Study: NCT06334419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules
Study: NCT06389006
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
Study: NCT06382311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 1 dose is administered to participants in Phase 2 Part B.
Study: NCT05386524
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin 30mg/m2 d1，q3w
Study: NCT05319834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: group 2: oral placebo once daily at the same time with progesterone
Study: NCT05893511
Drug: Antibiotics first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
Study: NCT05802108
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group was treated with statin only for lipid-lowering